Lung Cancer Treatments: How Decisions Are Made (NSCLC vs SCLC)

This guide is for patients and caregivers who want a clear but serious explanation of how lung cancer treatment decisions are made today.

Important: This is educational information, not medical advice. Treatment choices depend on cancer stage, pathology, biomarkers, overall health, and your preferences. Always review options with your oncology team.

60-second orientation (what matters most)

  • Lung cancer is treated as two major diseases: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC).
  • In NSCLC, the most important early step is often biomarker testing (tumor testing for mutations/fusions plus immune markers), because it can change first-line therapy.
  • Many NSCLC patients are treated based on whether the tumor has:
  • a targetable driver (often treated with targeted therapy), or
  • no driver (often treated with immunotherapy with or without chemotherapy).
  • In SCLC, treatment is usually chemotherapy-based; immunotherapy may be added in some settings.

Key terms (defined once)

  • NSCLC (non-small cell lung cancer): ~85% of lung cancers. Includes adenocarcinoma and squamous cell carcinoma.
  • SCLC (small cell lung cancer): ~15%. Often grows and spreads faster.
  • Biomarker testing: tests on the tumor (or sometimes blood) that help predict which treatments are likely to work.
  • NGS (next-generation sequencing): a tumor test that checks many genes at once to find mutations or fusions.
  • PD-L1: a tumor protein test that can help predict whether immunotherapy may work well.
  • Immunotherapy (checkpoint inhibitors): medicines that help the immune system recognize and attack cancer (often PD-1/PD-L1 drugs).
  • Targeted therapy: medicines designed to block a specific mutation or fusion the tumor depends on.

Step 1: “What type do I have?” (NSCLC vs SCLC)

Most treatment decisions start by confirming whether this is NSCLC or SCLC based on pathology.

If it’s NSCLC

NSCLC is treated as a set of subtypes. The most practical split is:

  • NSCLC with a targetable driver (mutation/fusion): targeted therapy is often first.
  • NSCLC without a targetable driver: immunotherapy with or without chemotherapy is often first.

If it’s SCLC

SCLC typically has fewer routinely targetable drivers, so treatment tends to be:

  • chemotherapy-based, sometimes combined with immunotherapy
  • plus radiation in certain situations

Step 2: “What stage is it?”

You’ll hear staging described in three broad buckets:

  • Early stage (localized): cancer appears confined to the lung/nearby nodes and may be removable or treatable with focused radiation.
  • Locally advanced: more lymph node involvement; treatment often combines radiation and systemic therapy.
  • Metastatic (stage IV): cancer has spread; treatment focuses on systemic therapy (medicines), sometimes with radiation for specific symptoms.

Your stage strongly affects whether the goal is cure vs long-term control.

Step 3 (NSCLC): Biomarkers that change first-line treatment

For many NSCLC patients—especially adenocarcinoma—teams often test for a set of “drivers” and immune markers. Examples you may hear:

  • Driver mutations/fusions: EGFR, ALK, ROS1, RET, MET exon 14 skipping, BRAF V600E, KRAS G12C, HER2 (ERBB2), NTRK fusions (and others depending on the panel).
  • Immune marker: PD-L1 level (reported as a percentage).

Why this matters:
A targetable driver can shift the entire treatment plan away from chemo-first and toward a targeted drug strategy.

What treatment typically looks like today (high-level, by scenario)

A) Early-stage NSCLC (often curative intent)

Typical options include:

  • Surgery (if removable and safe), sometimes followed by additional therapy depending on risk.
  • Radiation for patients who are not surgical candidates or as part of combined therapy.
  • In selected higher-risk situations, systemic therapy may be used before or after surgery (the exact approach depends on stage and biomarkers).

What to ask:

  • “Is surgery an option?”
  • “Do I need treatment before/after surgery?”
  • “Were biomarkers tested, and do they change the plan even in early stage?”

B) Metastatic NSCLC with a targetable driver (often targeted therapy first)

If the tumor has a driver mutation/fusion, many patients start with targeted therapy because it can:

  • produce rapid symptom improvement
  • achieve high response rates
  • sometimes control brain metastases better (depending on the drug)

Common real-world pattern: targeted therapy first → monitor → test for resistance at progression → next targeted option or switch to chemo/immunotherapy depending on biology and prior exposure.

What to ask:

  • “Which driver was found, and what drug targets it?”
  • “If this stops working, what’s the next step?”
  • “If the cancer changes, will we repeat testing (tumor or blood)?”

C) Metastatic NSCLC without a targetable driver (immunotherapy ± chemotherapy)

When no driver is found (or no targetable driver), treatment often uses:

  • immunotherapy alone in selected cases, or
  • immunotherapy + chemotherapy in many cases

A PD-L1 test can influence which of these is more likely.

What to ask:

  • “What is my PD-L1 level, and how does it change treatment?”
  • “Why immunotherapy alone vs combined with chemotherapy?”
  • “How will we monitor response and side effects?”

D) Small cell lung cancer (SCLC) overview

SCLC is often treated with:

  • chemotherapy-based regimens
  • immunotherapy added in some extensive-stage settings
  • radiation in specific situations (for example, symptom control or selected consolidation strategies)

SCLC can respond well initially, but relapse can occur, and options after relapse may be more limited—this is one reason research is very active here.

What to ask:

  • “Is this limited-stage or extensive-stage?”
  • “What’s the goal: cure vs control?”
  • “If it comes back, what would we consider next?”

Keep your care organized in VisitVizor

Create a free account to store scans, labs, and visit notes in one secure place.

Create free accountSign in

Educational content stays free — no paywall required.

Deep dive (for people who want the real decision map)

The NSCLC decision map (plain-English “if/then”)

If NSCLC and a targetable driver is present:

  • targeted therapy is often first-line
  • immunotherapy may be used later or in specific contexts
  • progression usually triggers repeat testing to look for resistance mechanisms

If NSCLC and no targetable driver is found:

  • PD-L1 level helps guide immunotherapy intensity
  • many patients receive immunotherapy + chemotherapy up front

If mixed signals (driver found but PD-L1 also high):

  • the driver generally takes priority in decision-making because driver-positive tumors can behave differently with immunotherapy; your oncologist will explain sequencing rationale.

(You don’t need to memorize this—this is a “framework” for understanding your plan.)

What “resistance” means (and why repeat testing matters)

Cancers evolve under treatment pressure. When a targeted therapy stops working, it may be because:

  • the cancer developed a new resistance mutation,
  • the tumor changed biology (less common but possible),
  • or the drug can no longer reach certain areas well (for example, the brain).

That’s why some teams use repeat tissue biopsy or blood testing (circulating tumor DNA) at progression to guide the next step.

What to ask at progression:

  • “Can we test the tumor again to understand why this stopped working?”
  • “Would a blood test be informative here?”
  • “Are there trials for my resistance profile?”

Understanding common report items (what to look for)

Ask for copies of:

  • pathology report
  • biomarker results (NGS report, PD-L1 report)
  • imaging summaries

On biomarker reports, useful items include:

  • the exact driver alteration (if present)
  • whether it’s considered “actionable” and with what therapy
  • PD-L1 percentage and testing method
  • whether the sample was tissue or blood and how recent it is

Side effects: what’s different across treatment types

  • Targeted therapy: often causes side effects like rash, diarrhea, fatigue, and other drug-specific effects; monitoring is tailored to the drug.
  • Immunotherapy: can cause immune-related side effects (inflammation in organs like skin, colon, lungs, liver, endocrine glands). These are uncommon but important to recognize early.
  • Chemotherapy: can cause fatigue, nausea, hair loss, low blood counts, neuropathy (depending on regimen).

Practical tip: ask your team for “red flag symptoms” that should trigger a call the same day.

Questions to bring to your next visit (high-value list)

  1. What exact type do I have: NSCLC or SCLC?
  2. What stage is it, and what is the main goal of treatment right now?
  3. What biomarker tests were done (NGS, PD-L1), and what were the results?
  4. Based on those results, what is the recommended first-line plan and why?
  5. How will we know if it’s working, and when will we reassess?
  6. If this treatment stops working, what are the next 2–3 options?
  7. Are there clinical trials that match my subtype or biomarkers?

Sources and review

This guide reflects common modern lung cancer decision concepts (stage + subtype + biomarker-driven therapy and sequencing).

Last reviewed: 2026-02-01